Efficacy of a Simple Dosage Scheme to Convert From Shorter-acting Erythropoiesis-stimulating Agent to Continuous Erythropoietin Receptor Activator in Kidney Transplantation Patients

Sánchez-Escuredo, Ana; Batista, Fatima; Cases, Aleix; Torregrosa, José-Vicente

doi:10.1016/j.transproceed.2014.12.006

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…89 Similarly, a 1-year study of 77 patients showed stable iron and creatinine levels and a small increase in hemoglobin levels after conversion from short-acting ESAs (epoetin alfa or darbepoetin alfa) to continuous erythropoietin receptor activator therapy at dosages of 50-150 mg/mo. 90…”

Section: Management Of Post-transplant Anemiamentioning

confidence: 99%

Treatment of anemia in difficult-to-manage patients with chronic kidney disease

Raichoudhury

Spinowitz

2021

Kidney International Supplements

View full text Add to dashboard Cite

The management of anemia of chronic kidney disease (CKD) is often challenging. In particular, for patients with underlying inflammation, comorbid type 2 diabetes or cancer, those hospitalized, and recipients of a kidney transplant, the management of anemia may be suboptimal. Responsiveness to iron and/or erythropoiesis-stimulating agents, the mainstay of current therapy, may be reduced and the risk of adverse reactions to treatment is increased in these difficult-to-manage patients with anemia of CKD. This review discusses the unique patient and disease characteristics leading to complications and suboptimal treatment response. New treatment options in clinical development, such as hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, may be particularly useful for difficult-to-treat patients. In clinical studies, HIF-PH inhibitors provided increased hemoglobin levels and improved iron utilization in anemic patients with nondialysis-dependent and dialysis-dependent CKD, and preliminary data suggest that HIF-PH inhibitors may be equally effective in patients with or without underlying inflammation. The availability of new treatment options, including HIF-PH inhibitors, may improve treatment outcomes in difficult-to-manage patients with anemia of CKD.

show abstract

Section: Management Of Post-transplant Anemiamentioning

confidence: 99%

Treatment of anemia in difficult-to-manage patients with chronic kidney disease

Raichoudhury

Spinowitz

2021

Kidney International Supplements

View full text Add to dashboard Cite

show abstract

Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure

Schmid

2015

Expert Review of Hematology

View full text Add to dashboard Cite

Since more than two decades erythropoiesis-stimulating agents are the main pillar for treatment of anemia associated with chronic kidney disease. Methoxy polyethylene glycol-epoetin beta (MPG-EPO), also called continuous erythropoietin receptor activator, is the longest acting erythropoiesis-stimulating agent currently available. MPG-EPO is characterized by an elimination half-life of approximately 137 h and offers extended dosing intervals up to 4 weeks. Numerous phase I/II studies and a comprehensive clinical phase III program demonstrated the feasibility of MPG-EPO therapy for anemia correction and maintenance of stable hemoglobin levels in adult chronic kidney disease patients. Due to patent disputes MPG-EPO was only available outside the US market so far. In view of a prevailing US market introduction, this review focuses on efficacy and safety data from pivotal trials, summarizes recent clinical research and finally tries to substantiate potential benefits associated with the use of this anti-anemic drug.

show abstract

Efficacy of a Simple Dosage Scheme to Convert From Shorter-acting Erythropoiesis-stimulating Agent to Continuous Erythropoietin Receptor Activator in Kidney Transplantation Patients

Cited by 2 publications

References 11 publications

Treatment of anemia in difficult-to-manage patients with chronic kidney disease

Treatment of anemia in difficult-to-manage patients with chronic kidney disease

Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure

Contact Info

Product

Resources

About